- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 92,010 | 01.07.24 17:35:51 | +1,840 | +2,04% | 0,000 | 0,000 | 91,250 | 90,170 |
|
Regeneron Pharmaceuticals | 881535 | NASDAQ | 1.057,020 | 01.07.24 22:00:09 | +5,990 | +0,57% | 1.056,480 | 1.057,020 | 1.054,810 | 1.051,030 |
